Products

New technologies to be adopted by the partner SMEs or to be sold to third parties. The quantitative goal is to generate two drug leads to treat each of the following conditions: brain tumour, blood tumour and metastatic circulating cells, and MRSA infection. Inherent to the previous deliverable, new Intellectual Property Rights (IPR) will be built from existing IPR of the partners.